No.2
The FDA granted fast track designation to devimistat for the treatment of pancreatic cancer, according to the agent’s manufacturer.
Devimistat (CPI-613, Rafael Pharmaceuticals) targets enzymes in the mitochondria of cancer cells that are involved in cancer cell energy metabolism.
The agent is designed to selectively target the mitochondrial tricarboxylic acid cycle in cancer cells. This process is essential to tumor cell multiplication and survival.
The FDA gave Rafael Pharmaceuticals approval to begin pivotal phase 3 trials in pancreatic cancer and acute myeloid leukemia.
返信
投資の参考になりましたか？
